Category Archives: Transhuman News

Moonshine S-off Update on the Droid DNA
Beaups, the Moonshine dev, helped me through the errors I was getting. I have the correct bootloader now thanks to him! Moonshine S-off video: http://youtu.b...

By: BrandonTalks2

See the article here:
Moonshine S-off Update on the Droid DNA - Video

High Intensity Cardio Series- Team Dna
High Intensity Cardio Series or HIIT is an enhanced form of interval training, an exercise strategy alternating periods of short intense anaerobic exercise w...

By: teamdnafitness

Original post:
High Intensity Cardio Series- Team Dna - Video

DNA repair and protection from oxidative damage

By: Vi #7877;n Ph greenfarm

Read the original:
DNA repair and protection from oxidative damage - Video

HTC DNA Video Test
This camera is supposed to be good, but it #39;s great.

By: Dave Kerwood

Read this article:
HTC DNA Video Test - Video

WOBURN, Mass., June 19, 2013 /PRNewswire/ -- LGC Genomics and Covaris, Inc. announced they are partnering to develop an innovative solution for the high-throughput extraction of Nucleic Acids from Formalin-Fixed, Paraffin Embedded (FFPE) tissue samples.

Covaris recently introduced a kit for high-yield DNA extraction from FFPE tissue samples. Covaris' patented Adaptive Focused Acoustic (AFA) Technology is used to emulsify and separate the paraffin, while simultaneously re-hydrating the tissue sample in an aqueous solution within a few minutes. Covaris Focused-ultrasonicators enable the purely mechanical processing of the samples, eliminating the need for organic solvents in the extraction process. DNA is efficiently extracted from FFPE samples with greater yield when compared to other commercially available solutions. It results in a simplified workflow, which improves reproducibility, reduces hands on time, and ensures the seamless integration with Next Generation Sequencing (NGS) and other analytical applications.

LGC Genomics has a long standing expertise in providing DNA extraction solutions, including a range of extraction technologies and the development of kits and systems optimized for specific applications. LGC Genomics' current product offerings include, sbeadexmagnetic microparticles and Kleargene spin plates for automated extraction of high quality DNA.

Building on the strengths of both companies, LGC Genomics and Covaris will integrate LGC Genomics' DNA purification solution with Covaris FFPE extraction workflow. This collaboration will offer a complete solution, from FFPE tissue to high quality DNA, suitable for high throughput applications with the ability to process thousands of FFPE samples per week.

FFPE is a widely used method for archiving tissue specimens; especially clinical samples. These archived samples are a rich resource for studying gene variations or gene expression profile changes, and have the promise of empowering advancements to clinical diagnostics and personalized medicine. However, extraction of DNA or RNA from FFPE tissue has traditionally been a challenge as it requires removing the paraffin, rehydrating the sample, and reversing the formaldehyde cross-links - resulting in low yields and poor quality of nucleic acid samples. Additionally, the traditional extraction processes require the use of hazardous or difficult-to-handle solvents causing barriers to automation and higher throughput processing. Covaris CEO, Jim Laugharn, commented, "This collaboration will provide a solution to overcome traditional short-comings and barriers. We will improve the extraction workflow and provide higher quality samples and higher quality results in a high throughput environment."Giulio Cerroni, LGC Genomics Managing Director added, "We are delighted to be working with Covaris to develop this application together. Linking our Sbeadex and Kleargene technologies with the Covaris technology will provide our customers in both pathology and research laboratories with a complete solution that will enable them to process FFPE samples significantly more efficiently, whilst also providing high yields, reproducibly."

See more here:
LGC Genomics and Covaris, Inc. Announce FFPE DNA Extraction Partnership

Contradictions and illogical conclusions in the ruling that freed US student Amanda Knox from jail mean DNA evidence will be re-examined from scratch and witnesses may be re-heard, her lawyer says.

'We were very surprised, we took it very badly,' Luciano Ghirga said in reference to a damning report released by Italy's highest appeals court explaining why it quashed the acquittal of Knox and her former boyfriend Raffaele Sollecito.

'The new court will re-examine all the evidence from the very start, with fresh expert evaluation and possibly fresh testimony from witnesses,' he said.

'We are ready to fight, to answer every challenge point by point,' he added.

Knox and Sollecito - originally sentenced to 26 and 25 years in prison for sexually abusing and killing Knox's British housemate Meredith Kercher - were acquitted by an appeals court in Perugia in 2011 after four years behind bars.

In March, however, Italy's highest appeals court overturned the acquittal and ordered a retrial in a Florence appeals court, citing 'numerous examples of shortcomings, contradictions and incoherencies' in the original appeal ruling.

The 74-page report accused the judges of glazing over clues and insisted the prosecution's claim from the original trial - that the grizzly murder was the result of 'an erotic game that spun out of control' - was a valid hypothesis.

'We had gone beyond that theory, proved there was nothing to it,' Ghirga said, while Sollecito's lawyer Giulia Bongiorno added: 'If there was an erotic game, most certainly Raffaele Sollecito and Amanda Knox were not part of it.'

Both Knox and Sollecito face a retrial in a Florence court, although no date has yet been set and Italy cannot compel the Seattle-born student to return.

Read more:
Experts to re-examine Knox DNA clues

DNA Oy, a Finnish wireless carrier, is weighing a sale to a private-equity firm and an initial public offering as options to broaden its ownership.

DNA, owned by a group of Finnish regional phone carriers led by Finda Oy, said its plans will become clearer within the next few months, according to a statement today. Keeping the current ownership structure is an option, the Helsinki-based company said.

A sale would provide the shareholders with cash, while potentially strengthening DNA against larger rivals Elisa Oyj (ELI1V) and TeliaSonera AB. (TLSN) The IPO could be the biggest in Finland, home of Nokia Oyj (NOK1V) and Angry Birds maker Rovio Entertainment Oy, since 2005.

DNAs market value is probably about 1.1 billion euros ($1.5 billion), Mikko Ervasti, an analyst at Evli Bank Oyj in Helsinki, said in March. Though the companys profitability has trailed rivals, it will probably boost margins this year and next as it adds subscribers and curbs costs, according to the analyst.

DNAs sales increased 5.7 percent to 769 million euros last year and earnings before interest, taxes, depreciation and amortization rose 1.2 percent to 191 million euros, according to its website. DNAs wireless service covers more than 5 million Finns and the company also owns a cable-television network in the Helsinki area.

To contact the reporter on this story: Adam Ewing in Stockholm at aewing5@bloomberg.net

To contact the editor responsible for this story: Ville Heiskanen at vheiskanen@bloomberg.net

Visit link:
Finnish Mobile Carrier DNA Weighs Sale to Private Equity or IPO

ROME (AFP) Contradictions and illogical conclusions in the ruling that freed US student Amanda Knox from jail mean DNA evidence will be re-examined from scratch and witnesses may be re-heard, her lawyer said Tuesday.

"We were very surprised, we took it very badly," Luciano Ghirga said in reference to a damning report released by Italy's highest appeals court explaining why it quashed the acquittal of Knox and her former boyfriend Raffaele Sollecito.

"The new court will re-examine all the evidence from the very start, with fresh expert evaluation and possibly fresh testimony from witnesses," he said.

"We are ready to fight, to answer every challenge point by point," he added.

Knox and Sollecito -- originally sentenced to 26 and 25 years in prison for sexually abusing and killing Knox's British housemate Meredith Kercher -- were acquitted by an appeals court in Perugia in 2011 after four years behind bars.

In March, however, Italy's highest appeals court overturned the acquittal and ordered a retrial in a Florence appeals court, citing "numerous examples of shortcomings, contradictions and incoherences" in the original appeal ruling.

The 74-page report accused the judges of glazing over clues and insisted the prosecution's claim from the original trial -- that the grizzly murder was the result of "an erotic game that span out of control" -- was a valid hypothesis.

"We had gone beyond that theory, proved there was nothing to it," Ghirga said, while Sollecito's lawyer Giulia Bongiorno added: "If there was an erotic game, most certainly Raffaele Sollecito and Amanda Knox were not part of it."

The report claimed a third trace of blood found on a knife recovered from the house Knox and Kercher lived in should have been examined and was not.

It found fault with the time-scale of the murder the appeals court followed, saying that the "harrowing scream" heard by several witnesses pushed back the time of the crime from between 21:00 and 21:30 local time to two hours later.

Read the original:
Experts to re-examine DNA clues in fresh Knox appeal

PISCATAWAY, N.J. , June 20, 2013 /CNW/ - On June 13, 2013 , the United States Supreme Court unanimously ruled that although isolated, natural gene sequences are unpatentable, cDNA (referred to as synthetic DNA) is officially considered patentable subject material. The ruling was issued after the court reviewed patents owned by Myriad Genetics Inc. in the high-profile case Association for Molecular Pathology v. Myriad Genetics. The patents claimed the genes BRCA1 and BRCA2, as well as methods for detecting mutations in the genes that have been linked to breast and ovarian cancer. The court supported this legal claim, stating that "cDNA is not a 'product of nature,' so it is patent eligible ".

GenScript's gene synthesis service is a valuable method for circumventing the isolation of natural DNA sequences for use in biological research studies. The service provides non-natural, de novo DNA sequences synthesized according to specified client design, allowing natural gene sequences or cassettes to be engineered for in vivo, or in vitro use, including diagnostic tests. Additionally, GenScript's OptimumGene(TM) codon optimization technology can alter the sequence of natural genes, to increase the expression of the subsequent protein in a number of systems. The OptimumGeneTM algorithm considers nearly every parameter affecting the central dogma process, from transcription to protein folding, and has been proven to optimize protein production in bacterial, mammalian, yeast and insect expression systems. OptimumGeneTM codon optimization in combination of gene synthesis can generate novel, non-naturally occurring sequences, with high-utility and attractive patentable features. To preserve clients' intellectual property rights, GenScript does not claim any rights to specialized synthetic or OptimumGeneTM codon optimized genes. Custom project details are kept strictly confidential; all intellectual property rights belong to the client.

It may be too soon to speculate on the court ruling's effect on DNA sequences' future patentability. However, as the pace of molecular biology research quickens, the use of synthetic DNA will inevitably become a mainstay in every lab. GenScript offers gene synthesis and codon optimization solutions for the present and future of gene patent law and remains committed to supporting innovation.

*GenScript is not a legal practitioner and the content above is in no way intended to provide legal advice for patent prosecution, litigation or any associated legal matters thereof.

SOURCE: GenScript USA Inc.

Go here to see the original:
Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway ...

- The company integrated on-the-spot DNA microchip-based test with a cloud-based server and gene-mapping engine to offer a rapid and robust cosmeceuticals solution

MOUNTAIN VIEW, California, June 20, 2013 /PRNewswire/ -- Based on its recent analysis of the personalized cosmeceuticals market, Frost & Sullivan recognizes geneOnyx Limited with the 2013 European Frost & Sullivan Award for New Product Innovation. geneOnyx leverages a DNA testing platform originally used for medical point-of-care testing to create an on-the-spot genetic test for anti-aging cosmetics.

geneOnyx's test requires only a single-step DNA collection procedure from saliva to examine single nucleotide polymorphisms (SNPs)or genetic variationsin key genes relating to important skin biochemical pathways. The sample is placed on a rapid lab-on-chip system, which is connected to a cloud-computing device linked to CosMos(TM), geneOnyx's patent-pending, cloud-based data analysis engine and ingredient library.

In 30 minutes, the system maps the personalized profile of the individual's genetic variations with compatible active ingredients and recommends a customized anti-aging serum that will be most effective for the individual. The DNA microchip will be securely disposed of immediately to ensure the confidentiality of the customer's profile.

"The DNA microchip is portable, resembling a USB memory stick, and enables testing outside the laboratory environment," said Frost & Sullivan Industry Analyst Vin Nee Lim. "geneOnyx DNA testing harnesses DNA Electronics' proprietary Genalysis(R) technology; geneOnyx(TM) obtained a worldwide exclusive license from DNA Electronics in 2012 for utilizing this technology in the cosmeceuticals sector."

The geneOnyx test is the first over-the-counter personalized genetic test. Dermatologists and cosmeticians find it highly useful in recommending skincare products with specific ingredients. As the test is user-friendly, they can easily be carried out by non-scientific trained personnel and conveniently performed in a retail setting.

geneOnyx's product will have a significant impact on the cosmetic industry by enabling an end-to-end customer service.

"The company is set to launch a flagship store in London with its own skincare range, developed in association with the genetic testing technology, providing customers with both personalized recommendations and a skincare regime solution," noted Lim. "geneOnyx's current services are focused on anti-aging skincare, but the testing system's application will extend to health and wellness as well."

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which, in turn, increases customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

Original post:
Frost & Sullivan Applauds geneOnyx for its DNA Testing Solution for the Personalized Cosmeceuticals Market